HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freitas, J. E. Articles by Sisson, J. C. Search for Related Content PubMed PubMed Citation Articles by Freitas, J. E. Articles by Sisson, J. C.

Iodine-131: Optimal Therapy for Hyperthyroidism in Children and Adolescents?

William Beaumont Hospital, Royal Oak, Michigan
University of Michigan Medical Center, Ann Arbor, Michigan

Correspondence: For reprints contact: John Freitas, Dept. of Nuclear Medicine, William Beaumont Hospital, 3601 W. 13 Mile Rd., Royal Oak, MI 48072.

ABSTRACT

To assess the medium- to long-term effects of I-131 therapy of hyperthyroidism in children and adolescents, we studied 51 patients (age range 6–18; 8 boys, 43 girls) treated with I-131 for Graves' disease with hyperthyroidism at the University of Michigan Medical Center (1951–1972). Patients received total doses ranging from 3 to 81.6 mCi. The mean followup period was 14.6 ± 7.9 yr. Hyperthyroidism was effectively treated in 49 within 1 to 12 mo. One patient failed to respond to three treatment doses, and hyperthyroidism recurred in two patients: 2 and 11 yr after initial therapy. Of these three patients, two were treated by thyroidectomy and one was retreated successfully with I-131. There were no cases of thyroid cancer, other malignancies or leukemia. The patients' reproductive histories and the health of their offspring were as in the general population. At the time of study, the prevalence of hypothyroidism was 92%, with no recurrent goiters or thyroid nodules. Iodine-131 is found to be safe and effective treatment of hyperthyroidism in children and adolescents and should be the preferred mode of therapy.

This article has been cited by other articles:

				A. Iagaru and I. R. McDougall Treatment of Thyrotoxicosis J. Nucl. Med., March 1, 2007; 48(3): 379 - 389. [Abstract] [Full Text] [PDF]

				S. A. Rivkees and E. A. Cornelius Influence of Iodine-131 Dose on the Outcome of Hyperthyroidism in Children Pediatrics, April 1, 2003; 111(4): 745 - 749. [Abstract] [Full Text] [PDF]

				S. A. Rivkees, C. Sklar, and M. Freemark The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3767 - 3776. [Full Text]

				D. S. Cooper Radioiodine for Hyperthyroidism: Where Do We Stand After 50 Years? JAMA, July 22, 1998; 280(4): 375 - 376. [Full Text] [PDF]

				T D CHEETHAM, I A HUGHES, N D BARNES, and E P WRAIGHT Treatment of hyperthyroidism in young people Arch. Dis. Child., March 1, 1998; 78(3): 207 - 209. [Full Text]